Open-Label Adalimumab for Ulcerative Colitis Patients
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
This is an open-label study of 20 patients designed to demonstrate the safety, tolerability
and preliminary evidence of benefit of adalimumab in the treatment of subjects with
Ulcerative Colitis, both in patients who have never received anit-TNF agents and in those who
have lost response or developed intolerance to previous infliximab therapy.